SCHEMBL16469258

SCHEMBL16469258

O=S(=O)(Cl)c1cccn1S(=O)(=O)c1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.48
HSD17B10 Q99714 1/20 0.48
TDP1 Q9NUW8 1/20 0.48
HTR6 P50406 6/20 0.47
MEN1 O00255 1/20 0.47
LMNA P02545 1/20 0.47
HPGD P15428 1/20 0.47
TSHR P16473 1/20 0.47
HTT P42858 1/20 0.47
KMT2A Q03164 1/20 0.47
PPME1 Q9Y570 2/20 0.45
RAPGEF4 Q8WZA2 2/20 0.41
MET P08581 1/20 0.41
CYP2C19 P33261 1/20 0.41
APEH P13798 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
CYP2C9 P11712 1/20 0.39
MMP2 P08253 1/20 0.39
PARL Q9H300 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL28058142 0.80 PPME1 (0.48) ALDH1A1HTR6MEN1LMNAHPGD
SCHEMBL28189646 0.77 HTR6 (0.50) ALDH1A1HSD17B10TDP1HTR6MEN1
SCHEMBL27662268 0.74 PPME1 (0.49) ALDH1A1HTR6MEN1LMNAHPGD
SCHEMBL28139909 0.73 PPME1 (0.51) ALDH1A1HTR6MEN1LMNAHPGD
SCHEMBL1599348 0.73 HTR6 (0.50) ALDH1A1HTR6MEN1LMNAHPGD
SCHEMBL14760380 0.73 HTR6 (0.50) ALDH1A1HTR6MEN1LMNAHPGD
SCHEMBL1599343 0.73 HTR6 (0.50) ALDH1A1HTR6MEN1LMNAHPGD
SCHEMBL30317840 0.73 ALDH1A1 (0.42) ALDH1A1HSD17B10TDP1HTR6MEN1
SCHEMBL10176180 0.70 HTR6 (0.47) ALDH1A1HTR6MEN1LMNAHPGD
SCHEMBL17900455 0.70 PPME1 (0.49) ALDH1A1TDP1HTR6MEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11459296-B2 Antibacterial compounds Infex Therapeutics Limited (GB) 2022-10-04 US disclosed
US-20210230115-A1 Antibacterial Compounds Infex Therapeutics Limited (GB) 2021-07-29 US disclosed
US-9533985-B2 Sulfonamide derivative and medicinal use thereof EA PHARMA CO., LTD. (JP) 2017-01-03 US disclosed
US-9533985-B2 Sulfonamide derivative and medicinal use thereof EA PHARMA CO., LTD. (JP) 2017-01-03 US disclosed
EP-2842945-B1 SULFONAMIDE DERIVATIVE AND MEDICINAL USE THEREOF EA PHARMA CO LTD (JP) 2016-10-26 EP disclosed
EP-2842945-A1 SULFONAMIDE DERIVATIVE AND MEDICINAL USE THEREOF AJINOMOTO CO., INC. (JP) 2015-03-04 EP disclosed
CN-104395297-A Sulfonamide derivatives and pharmaceutical use thereof AJINOMOTO KK 2015-03-04 CN disclosed
US-20150051395-A1 SULFONAMIDE DERIVATIVE AND MEDICINAL USE THEREOF AJINOMOTO CO., LTD. (JP) 2015-02-19 US disclosed
US-20150051395-A1 SULFONAMIDE DERIVATIVE AND MEDICINAL USE THEREOF AJINOMOTO CO., LTD. (JP) 2015-02-19 US disclosed
US-20150051395-A1 SULFONAMIDE DERIVATIVE AND MEDICINAL USE THEREOF AJINOMOTO CO., LTD. (JP) 2015-02-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210230115-A1 Antibacterial Compounds GAA, MGAM, NQO1 ALDH1A1 291/4885HSD17B10 308/4885TDP1 4465/4885
US-11459296-B2 Antibacterial compounds GAA, MGAM, NQO1 ALDH1A1 291/4885HSD17B10 308/4885TDP1 4465/4885
US-20150051395-A1 SULFONAMIDE DERIVATIVE AND MEDICINAL USE THEREOF ITGB4, ITGA4, ITGA2 ALDH1A1 1151/4885HSD17B10 4530/4885TDP1 4743/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.